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The intestinal immune system is regulated by microbes and their metabolites. The roles
of gut microbial metabolites in regulating intestinal inflammation and tumorigenesis are
incompletely understood. We systematically studied the roles of short-chain fatty acids
(SCFAs) and their receptors (GPR43 or GPR41) in regulating tissue bacterial load, acute ver-
sus chronic inflammatory responses, and intestinal cancer development. SCFA receptor-,
particularly GPR43-, deficient mice were defective in mounting appropriate acute immune
responses to promote barrier immunity, and developed uncontrolled chronic inflam-
matory responses following epithelial damage. Further, intestinal carcinogenesis was
increased in GPR43-deficient mice. Dietary fiber and SCFA administration suppressed
intestinal inflammation and cancer in both GPR43-dependent and independent manners.
The beneficial effect of GPR43 was not mediated by altered microbiota but by host tis-
sue cells and hematopoietic cells to a lesser degree. We found that inability to suppress
commensal bacterial invasion into the colonic tissue is associated with the increased
chronic Th17-driven inflammation and carcinogenesis in the intestine of GPR43-deficient
mice. In sum, our results reveal the beneficial function of the SCFA-GPR43 axis in sup-
pressing bacterial invasion and associated chronic inflammation and carcinogenesis in
the colon.
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Introduction
The intestine harbors a myriad of commensal microorganisms,
which benefit the host in many ways [1, 2]. Digestion resistant-
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dietary materials reach the colon for microbial fermentation. A
major group of dietary materials processed by microbial fermen-
tation includes dietary fibers (DF) and resistant starch. They
are fermented to produce short-chain fatty acids (SCFAs), which
play diverse roles from fueling colonocytes to regulating cells of
the immune system, energy storage/metabolism, and gut barrier
function [3–14].
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SCFAs exert their functions in the host through both SCFA
receptor-dependent and independent mechanisms [3]. SCFA
receptors include G-protein-coupled receptors (GPCRs) such as
GPR43, GPR41, GPR109A and Olfr78. GPR43 and GPR41 are
activated by all major SCFAs such as acetate (C2), propionate
(C3), and butyrate (C4) [15, 16]. GPR109A is activated by C4
along with a non-SCFA ligand, niacin [17]. Olfr78 is activated by
C2 and C3, but not C4 [18]. Triggering these receptors induce
activation of heterotrimeric G proteins and many downstream sig-
naling molecules, including MAPK/ERK proteins [13, 16, 19, 20].
GPR43, GPR41 and GPR109A are differentially expressed by many
cell types, including gut epithelial cells, macrophages, and den-
dritic cells [13, 15, 16]. Olfr78 is expressed in kidney endothelial
cells [18].
Inflammation is a major risk factor for cancer development in
the digestive tract [21–24]. Colon cancer is increased in patients
with inflammatory bowel diseases, such as ulcerative colitis and
Crohn’s disease. Similarly, celiac disease and Crohn’s disease
are risk factors for small intestinal cancer. It has been docu-
mented that high SCFA levels and DF intake decrease colon
cancer development [25]. GPR43 expression is decreased in
tumor cells and this receptor functions to suppress colon can-
cer development [26–28]. Employing acute or chronic dextran
sodium sulfate (DSS)-induced colitis models, two groups found
that GPR43 has heterogeneous effects on DSS-induced inflam-
matory responses [29, 30]. GPR43 and GPR41 are required for
mounting acute inflammatory responses following gut barrier
breach [13, 29], which would be important for barrier repair
and tissue bacterial clearance. GPR43 functions to increase benefi-
cial Bifidobacterium species but suppress inflammatory Helicobac-
ter hepaticus and Prevotellaceae [27], and cohousing of Gpr43−/−
mice with wild-type (WT) littermates suppressed acute 2% DSS-
induced colitis [28]. However, it is also reported that DF suppress
inflammation-associated colon cancer development in a manner
independent of the microbiota change but dependent on another
SCFA receptor GPR109A [31]. In this regard, DF or SCFA-receptor-
associated microbiota effect on inflammation-associated colon
cancer development is unknown. Moreover, the differential effect
of the SCFA-SCFA receptor axis on acute versus chronic responses
should be studied to better understand the working mechanisms
of DF, SCFAs and their receptors in suppressing colon cancer
development.
In this study, we addressed two critical issues regarding the
role of the SCFA-SCFA receptor axis in regulating inflammation
and cancer. First, we systematically determined the impact of
SCFAs and their receptors, with the focus on GPR43, on tissue
bacterial load and acute versus chronic inflammatory responses
and how this relates to colon cancer development. Second, we
interrogated whether the function of GPR43 is dependent on
microbiota difference between WT and Gpr43−/− mice employ-
ing cohoused mice. Our work demonstrates the importance
of the SCFA receptor-dependent barrier immunity in regulat-
ing bacterial invasion, subsequent inflammatory responses and
colon cancer development in a microbiota change-independent
manner.
Results
SCFA receptors promote acute but suppress chronic
inflammatory responses
To systematically understand the roles of SCFA receptors in regu-
lating inflammation, we compared the inflammatory responses of
WT and SCFA receptor (Gpr43 and Gpr41)-deficient mice induced
with DSS administered in acute and chronic inflammatory regi-
mens. In response to an acute inflammation-inducing DSS treat-
ment regimen (3.5% of DSS for 5 days and euthanized at day 9),
SCFA receptor-deficient mice were hypo-responsive in mounting
inflammatory responses at this early time point. Compared to WT
mice, they lost less weight, had longer colons, failed to increase
the frequencies of gut effector T cells (Th1 and Th17) and neu-
trophils, and did not up-regulate the mRNA expression of inflam-
matory cytokines and chemokines such as Il18, Il22, Il6, and Cxcl1
(Fig. 1; Supporting Information Figs. 1 and 2A and B). Increased
frequencies of Tregs were detected in Gpr43−/− mice. In general,
Gpr43−/− mice were more defective in mounting the acute inflam-
matory response than Gpr41−/− mice.
In response to a chronic inflammation-inducing DSS treatment
regimen (3 cycles of 1.5% DSS for 6 weeks), Gpr43−/− mice suf-
fered less initially but more in the late phase based on weight
change and stool score (Fig. 2A). However, Gpr41−/− mice were
not different from WT mice in the late phase. At termination fol-
lowing the chronic DSS treatment, Gpr43−/− mice had signs of
more severe inflammation based on colon length and frequen-
cies of inflammatory T cells (Th1 and Th17 cells) and neutrophils
(Fig. 2B–D, Supporting Information Fig 2C and D). In general,
the expression of inflammatory cytokines, such as Il18, Il22 and
Il6, was higher in SCFA receptor-deficient mice (Fig. 2E). Overall,
these results indicate that the SCFA receptor GPR43 suppresses
chronic inflammatory responses.
GPR43 functions to suppress Th17-driven
inflammatory response and intestinal carcinogenesis
Inflammation induces production of cytokines and genotoxic
reactive oxygen and nitrogen species, which cause mutations
and epithelial damages. These events compromise gut barrier
function and cause bacterial invasion, further increasing inflam-
matory responses leading to epithelial transformation [32–35].
Thus, we determined the impact of SCFA receptor deficiency
on azoxymethane (AOM)/DSS-induced carcinogenesis. We found
that Gpr43−/− mice initially suffered less from AOM/DSS-induced
weight loss, and diarrhea the first 3–4 weeks but more in the
late phase (Fig. 3A, Supporting Information Fig. 3). The effect of
GPR41 deficiency on cancer development was not as clear as in
GPR43 deficiency, which mirrors the weak effect of GPR41 defi-
ciency on chronic inflammation (Supporting Information Fig. 3
and Fig. 2). Because of its clear function in suppressing DSS-
induced chronic inflammation and AOM/DSS-induced cancer,
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Figure 1. Acute DSS-induced inflammatory responses in WT and SCFA receptor-deficient mice. (A) Body weight change (%) and stool score during
DSS-induced acute inflammation. (B) Colon length of WT, Gpr41−/− and Gpr43−/− mice after 3.5% DSS treatment. (C) Frequency of IFN-γ+, IL-17A+,
and FoxP3+ cells among intestinal lamina propria (LP) CD4+ T cells of WT, Gpr41−/− and Gpr43−/− mice. (D) Frequency of Gr-1+CD11b+ cells in
colonic LP cells of WT, Gpr41−/− and Gpr43−/− mice. (E) Expression of inflammatory cytokine and chemokine genes in colonic tissues of WT, Gpr41−/−
and Gpr43−/− mice. mRNA expression was measured by qRT-PCR and normalized to β-actin (Actb). Mice received 3.5% DSS in drinking water for
5 days before they were fed regular water prior to sacrifice at day 9. Representative and pooled data obtained (mean ± SEM, n = 8–10) from two
independent experiments are shown. For panel A, once significant group effects are established, pairwise differences between WT and Gpr41−/−
or Gpr43−/− on days 8 and 9 were separately examined. Group effects were significant for weight change (p = 0.0009) and for stool score (p = 0.02)
with repeated measures ANOVA. * Significant differences from WT with two-sample t-tests with Bonferroni’s adjustments for four comparisons
(significance at 0.0125 for each). For panel B–E, one-way ANOVA followed by Tukey’s multiple comparisons test was used to determine significance
between all pairs of groups. * Significant differences between indicated pairs (p < 0.05).
we focused the remaining study on GPR43. At 10 weeks post-
AOM treatment, Gpr43−/− mice had greater numbers of polyps
and advanced (bigger) adenomas often with complete loss of
crypts, medullary inflammatory cells (I) and necrotic abscesses
(N) (Fig. 3B and C). Further, they had enlarged spleen and mesen-
teric lymph nodes (MLN, Fig. 3D), which indicate active systemic
and intestinal inflammatory responses respectively.
It has been documented that GPR43-deficient mice have altered
microbiota [27, 28] and, therefore, it is possible that the pro-
tective effect of GPR43 is mediated by the altered microbiota.
To determine this, we induced AOM/DSS-induced colon can-
cer in co-housed mice and mice with shared bedding, both of
which were effective in creating the same shared microbiota pro-
file based on 16S rRNA gene quantitative (q)-PCR of selected
bacterial groups such as Firmicutes (Lachnospiraceae), Firmi-
cutes (Lactobacillus), Firmicutes (SFB), Bacteroidetes (Porphy-
romonadaceae), Bacteroidetes (B. fragilis), and Proteobacteria
(Enterobacteriale) (Supporting Information Fig. 4). Gpr43−/−
mice maintained the same increased susceptibility to AOM/DSS-
induced colon cancer even after the microbiota-equalization pro-
cedures (Fig. 4A and B). In the colon, the frequencies of Th17 cells
and neutrophils were increased whereas there was no change in
those of Th1 and FoxP3+ Tregs (Fig. 4C). In addition, increased
organ weight and frequencies of Th1, Th17 and Treg cells were
detected in the spleen and MLN, indicating elevated systemic and
intestinal inflammation (Fig. 4D and E). We also examined the
immune cell profile at an early stage (16–17 days after AOM injec-
tion) in co-housed mice. We observed longer colon, somewhat
decreased numbers of CD4+ T cells and increased frequencies of
Th17 cells in the colon of Gpr43−/− mice at this early stage of
carcinogenesis (Supporting Information Fig. 5). Thus, sustained
high Th17-driven inflammatory response is the characteristic
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Figure 2. Chronic DSS-induced inflammatory responses in WT and SCFA receptor-deficient mice. (A) Body weight change (%) and stool score
during DSS-induced chronic inflammation. (B) Colon length of WT, Gpr41−/− and Gpr43−/− mice after 3 cycles of 1.5% DSS treatment. (C) Frequency
of Gr-1+CD11b+ cells in the colonic LP cells of WT, Gpr41−/− and Gpr43−/− mice. (D) Frequency of IFN-γ+, IL-17A+, and FoxP3+ cells among LP
CD4+ T cells of WT, Gpr41−/− and Gpr43−/− mice. (E) Expression of inflammatory cytokine and chemokine genes in colon tissues isolated from
WT, Gpr41−/− and Gpr43−/− mice. mRNA expression was measured. Mice received 3 cycles of 1.5% DSS for 7 days followed by regular water for
7 days. Representative and pooled data (mean ± SEM, n = 8–10) from two independent experiments are shown. For panel A, once significant group
effects for early and late phases are established, differences between WT and Gpr41−/− or Gpr43−/− on specific days were separately examined by
phases. Significant group effects were seen in early phase (p = 0.034 for weight change and p = 0.026 for stool score) and in late phase (p < 0.001
for weight loss, and p = 0.010 for stool score) with repeated measures ANOVA. Differences from WT were further examined with multiple t-tests
on day 11 and 14 of early and day 38 and 40 of late phase for weight change and day 10 and 15 for early and 35 and 40 for late phase for stool
score. * Significant difference from WT with Bonferroni’s adjustments for four comparisons on each day within each phase (significance at 0.0125
for each). For panel B–E, one-way ANOVA followed by Tukey’s multiple comparisons test was used to determine significance between all pairs of
groups. * Significant differences between indicated pairs.
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Figure 3. AOM/DSS-induced colon cancer development in WT versus GPR43-deficient mice. (A) Changes in body weight (%), and stool scores of
WT and Gpr43−/− mice during AOM/DSS treatment. (B) Tumor burden (adenoma number) in the colon of WT and Gpr43−/− mice. (C) Histological
assessment of colon tissues of WT and Gpr43−/− mice. Paraffin-embedded tissue sections (6 μm) were stained with hematoxylin and eosin.
Medullary inflammatory cells (I) and necrotic abscesses (N) are marked in the picture. (D) Enlargement of spleen and MLN following AOM/DSS
treatment. The broken line indicates average weight of the indicated organs of untreated age-matching control WT mice. Mice were treated with
AOM (10 mg/Kg of body weight, i.p.) and three cycles of 1% DSS in drinking water and sacrificed at day 70 post AOM injection. Representative and
pooled data (mean ± SEM, n = 8–12) from three independent experiments are shown. For panel A, significant differences between Gpr43−/− and WT
were separately examined for early and late phases, followed by pairwise comparisons on specific days with Bonferroni adjustments for multiple
comparisons. Differences from WT were further examined using multiple t-tests with Bonferroni’s adjustments for 8 comparisons on day 42, 46,
49, and 53 for weight change (significance at p < 0.0063) and for 4 comparisons on day 3 and 9 in early phase and for 8 comparisons day 43, 48, 53,
and 59 in late phase for stool score (significance for each at p < 0.0125 and p < 0.0063). * Significant differences from WT obtained with t-tests. For
panel B, D, Mann–Whitney U test was performed with * indicating for significant differences (p < 0.05).
phenotype of Gpr43−/− mice during the colon cancer develop-
ment. Importantly, this phenotype was detected in the absence of
microbial changes due to GPR43 deficiency.
Next, we employed another intestinal cancer model (APCMin/+
mice) to verify the protective role of GPR43. This model devel-
ops spontaneous adenomas in both the small intestine and colon.
Gpr43−/− APCMin/+ mice developed more tumors in the small
intestine and colon than APCMin/+ mice, with greater numbers
of adenomas (Fig. 5A and C). Histological analysis revealed dis-
ordered epithelial cancer continuous from intestinal crypts in
the intestine of Gpr43−/− APCMin/+ mice (Fig. 5B). The spleen
and MLN of Gpr43−/− APCMin/+ mice were abnormally enlarged
(Fig. 5D).
Gpr43 is expressed by both tissue cells and hematopoietic cells,
including gut epithelial cells, enteroendocrine L cells, adipocytes,
eosinophils, basophils, neutrophils, monocytes, dendritic cells,
mucosal mast cells, and myometrium endothelium [3]. To deter-
mine the relative importance of tissue versus hematopoietic cells
in mediating the protective function of GPR43 on colon cancer,
we performed a bone marrow (BM) transplantation study. We
induced colon cancer with AOM/DSS in these mice and measured
weight change, tumor burden, and lymphoid tissue enlargement.
While differences between groups in not all the readouts were
statistically significant, there was a trend that the “Gpr43−/− (BM
donor)→Gpr43−/− (recipient)” group was most susceptible, fol-
lowed by the “WT→Gpr43−/−” group, and then by the “Gpr43−/−
→WT” group (Fig. 6). Thus, both cell types may mediate the pro-
tective effect of GPR43, but it was the non-hematopoietic tissue
cells that play a major role.
GPR43 partially mediates the protective effect of DF
and SCFAs
DF and SCFAs have SCFA receptor-independent functions. For
example, SCFAs function as histone deacetylase (HDAC) inhibitors
or metabolic regulators [36], which do not require SCFA recep-
tors. To determine if the protective effect of DF on AOM/DSS-
induced colon cancer is GPR43-dependent, WT and Gpr43−/− mice
were fed low-fiber diet (LFD, 0% soluble DF: 1:1 = pectin and
inulin), medium-fiber diet (MFD, 5% soluble DF), or high-fiber
diet (HFD,15% soluble DF) and were examined for their suscep-
tibility to AOM/DSS-induced carcinogenesis. As demonstrated in
the literature, DF suppresses colon cancer development in WT
mice in a dose-dependent manner (Fig. 7). DF also suppressed
carcinogenesis in Gpr43−/− mice but this effect was smaller than
that in WT. This indicates that DF can suppress carcinogenesis in
both Gpr43-dependent and independent manners.
We next studied if GPR43 mediates the protective effect of C3.
C3 was chosen because it is a high affinity ligand for GPR43 and an
efficient inhibitor of HDACs [15, 16, 37]. The increased AOM/DSS-
induced cancer development, along with spleen enlargement, in
LFD-fed WT mice was suppressed by C3 administered in drinking
water (Fig. 8A and B). C3 decreased cancer formation and spleen
enlargement in WT mice and in Gpr43−/− mice to a lesser degree
(Fig. 8C and E). Interestingly, C3 and DF (i.e. MFD) had additive
suppressive effects on cancer development and spleen enlarge-
ment (Fig. 8C–E). Overall these results indicate that DF and C3
suppress cancer development in Gpr43-dependent and indepen-
dent manners.
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Figure 4. AOM/DSS-induced colon cancer development and T cell responses in co-housed GPR43-deficient mice. (A) Gross colon images of co-
housed WT and Gpr43−/− mice. (B) Tumor formation (polyp number) in the colon and colon length (mm) of co-housed WT and Gpr43−/− mice. (C)
Effector T cells, Tregs and neutrophils in the colon of co-housed mice. (D) Spleen weight and T helper cell subset frequencies in the spleen of
co-housed mice. (E) MLN weight and effector T cells and Tregs in the MLN of co-housed mice. In panel D and E, the broken lines indicate average
weight of the indicated organs of untreated age-matching WT mice. To equalize microbiota between WT and Gpr43−/− mice, female mice were
co-housed at least one week prior to and until termination of the experiments. Alternatively, male mice were housed on mixed bedding (20%
of used bedding equally from WT and Gpr43−/− mice and 80% new bedding; changed twice a week). The data from these two experiments were
similar and all data were combined. Mice were treated with AOM (10 mg/Kg of body weight, i.p.) and 3 cycles of 1% DSS in drinking water and
sacrificed at day 62–63 post AOM injection. Representative and pooled data (mean ± SEM, n = 8–12) from three independent experiments are
shown. * Significant differences (p < 0.05, Mann–Whitney U test) from AOM/DSS-treated WT mice.
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Figure 5. Intestinal tumor formation in WT versus
Gpr43−/− ApcMin/+ mice. (A and B) Images and his-
tological assessment of intestine tissues. Tumor for-
mation in the small intestine and colon ApcMin/+ and
ApcMin/+Gpr43−/− mice. (C) Histological assessment of
intestine tissues. (D) Enlargement of spleen and MLN
in ApcMin/+ and ApcMin/+Gpr43−/− mice. ApcMin/+ and
ApcMin/+Gpr43−/− mice were sacrificed at 4 months
of age. In panel D, the broken lines indicate aver-
age weight of the indicated organs of untreated age-
matching WT mice. Representative and pooled data
(mean ± SEM; n = 6) from two experiments are shown.
* Significant differences from ApcMin/+ mice (p < 0.05,
Mann–Whitney U-test).
Increased tissue bacterial load contributes to
intestinal carcinogenesis in Gpr43−/− mice
Defective regulation of gut permeability in inflammatory condi-
tions has been reported for Gpr43−/− mice [13]. We found that
the expression of ocln (the gene for Occludin) at mRNA level was
greatly decreased in the colon of Gpr43−/− mice after 3 cycles
of 1.5% DSS treatment (Fig. 9A). C3 increased the expression of
ocln and tjp1 (the gene for ZO-1) in the colon of WT mice but
failed to increase their expression in Gpr43−/− mice. Consistently,
gut permeability was higher in Gpr43−/− than WT mice following
the chronic DSS treatment (Fig. 9B). We performed fluorescent
in situ hybridization (FISH) for eubacterial 16S RNA gene and q-
PCR analysis to detect bacteria in colon tissues. The abnormal gut
permeability in Gpr43−/− mice was supported by increased lev-
els of eubacteria in colon tissues (Fig. 9C). We found that many
more bacteria were detected within the colon tissues of Gpr43−/−
compared to WT mice during chronic inflammation. Importantly,
Figure 6. Comparison of non-hematopoietic and hematopoietic GPR43 in suppressing colon cancer. (A) Weight change (%) of mice during AOM/DSS
treatment. (B) Tumor formation (number and size) in the colon. (C) Enlargement of spleen and MLN. BM from WT or Gpr43−/− mice (10 million cells)
were transferred into lethally irradiated WT or Gpr43−/− mice, and the chimera mice were treated with AOM/DSS for induction of colon cancer.
Chimeras were treated with AOM (10 mg/Kg of body weight, i.p.) and 3 cycles of 1% DSS in drinking water and sacrificed at day 70 post-AOM
injection. Representative and pooled data (mean ± SEM, n = 7–9) from two independent experiments are shown. For panel A, group effect was
examined for late phase (days 35–70), and upon establishing significant group effect, pairwise comparisons on specific days (days 55, 60, 65, and 70)
were done with Bonferroni adjustments for multiple comparisons. Significant group effect was seen in weight change (p < 0.0001) using repeated
measures ANOVA during late phase. * Significant differences from WT → WT group on days 55–70, obtained with multiple t-tests with Bonferroni’s
adjustments for eight multiple pairwise comparisons (significance at p < 0.0063). For panel B-C, one-way ANOVA followed by Tukey’s multiple
comparisons test was used to make all pairwise comparisons. * Significant differences between indicated pairs.
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Figure 7. Effect of DF on AOM/DSS-
induced colon cancer development in WT
and Gpr43−/− mice. (A) Colon tissues of
WT or Gpr43−/− mice fed different levels
of DF (LFD, MFD, and HFD) and treated
with AOM/DSS. (B) Weight change (%) of
WT and Gpr43−/− mice during AOM/DSS
treatment. (C) Tumor formation in the
colon of WT and Gpr43−/− mice. Mice were
treated by AOM (10 mg/Kg of body weight,
i.p.) and 3 cycles of 1% DSS in drinking
water and sacrificed at day 70 post AOM
injection. Representative and pooled data
(mean ± SEM, n = 8–10) from two indepen-
dent experiments are shown. For panel
B, within each of WT and Gpr43−/− type,
diet effect was examined for late phase
(days 35–70), and when significant effect
was established, pairwise comparisons
on specific days (65 and 70) were done
with Bonferroni adjustments for multiple
comparisons. Significant diet effects for
late phase (p < 0.0001) was seen using
repeated measures ANOVA in WT mice.
* Significant differences from LFD mice
on day 65 and 70 with t-tests (signifi-
cance at p < 0.0125). For panel C, one-
way ANOVA followed by Tukey’s multi-
ple comparison test was used to make all
pairwise comparisons. * Significant differ-
ences between indicated pairs.
C3 feeding decreased tissue bacteria (Fig. 9C). We also exam-
ined tissue bacteria during AOM/DSS-induced carcinogenesis in
the colon. Tissue bacterial load was not different in co-housed WT
and Gpr43−/− mice at an early stage but later it was decreased in
WT but remained elevated in Gpr43−/− mice (Fig. 9D), indicating
defective control of tissue bacterial load at the chronic stage in
GPR43 deficiency.
To understand the role of the increased tissue bacteria in
Gpr43−/− mice, mice were treated with antibiotics during intesti-
nal carcinogenesis. Antibiotics suppressed AOM/DSS-induced
Figure 8. Effect of propionate on
AOM/DSS-induced colon cancer devel-
opment in WT and Gpr43−/− mice. (A)
Tumor formation in the colon of WT
mice fed LFD alone or LFD and C3 (80
mM). (B) Enlargement of spleen fol-
lowing AOM/DSS treatment. (C) Tumor
formation in the colon of mice fed
indicated diet and drinking water. (D)
Histological assessment of colon tissues.
Paraffin-embedded tissue sections (6
μm) were stained with hematoxylin
and eosin. (E) Spleen enlargement. Mice
were fed indicated diet and drinking
water and treated with AOM (10 mg/Kg
of body weight, i.p.) and 3 cycles of 1%
DSS in drinking water and sacrificed
at day 70 post AOM injection. Repre-
sentative and pooled data (mean ±
SEM, n = 8–12) from three independent
experiments are shown. For panel A
and B, Mann–Whitney U test was used
for significant differences between
two groups *. For panel C and E, in
both WT mice and Gpr43−/− mice, no
interaction of C3 by MFD was found
with two-way ANOVA. For both panel
C and E, we found significant overall
C3 effect (p < 0.0001 for panel C, p =
0.0212 for panel E) and MFD effect (p <
0.0001 for panel C, and p = 0.0108 for
panel E).
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Figure 9. Effects of propionate and GPR43 on gut barrier function and tissue bacterial load during inflammation and colon cancer development
in WT versus Gpr43−/− mice. In panel A-C, WT and Gpr43−/− mice were fed regular rodent chow and C3 (80 mM) in drinking water and treated
with 3 cycles of 1.5% DSS and regular water. (A) Expression of tight junction protein genes (ocln and tjp1) at mRNA level in colon tissues of WT
and Gpr43−/− mice after DSS treatment. qRT-PCR was performed. (B) Gut permeability in WT and Gpr43−/− mice after DSS treatment. Shown is
FITC-dextran concentration in blood. (C) Tissue-associated bacteria in the colon following DSS treatment. Confocal microscopy and q-PCR was
performed. For q-PCR, DNA isolated from colon tissues was PCR-amplified with primers for total eubacteria and the mouse β-actin gene. Relative
levels of eubacterial levels normalized by β-actin gene signals and then by control WT levels are shown. (D) Tissue bacteria load in co-housed mice
following AOM/DSS-induced colon cancer. Mice were treated with AOM and 3 cycles of 1% DSS in drinking water and sacrificed at day 16–17 or
62–63 post AOM injection. (E) Tumor formation in the colon from WT and Gpr43−/− mice with or without antibiotics treatment. Representative and
pooled data (mean ± SEM, n = 7–9 mice) from two experiments are shown. For all panels, two-way ANOVA with an interaction for the two factors
was used, and for each panel A, D, and E, a significant interaction term (each p < 0.001) was found. Follow-up multiple 2-sample t-tests were done
for pair-wise comparisons with Bonferroni adjustment for six pairwise comparisons for each panel. * Significant t-tests at p < 0.008. For panel B
and C, interaction of C3 by Gpr43 was not significant for both gut permeability and for tissue bacteria. Two-way ANOVA with main factors only
found significant Gpr43 (p < 0.0001) and C3 (p = 0.042) effect for gut permeability (B) and significant Gpr43 (p < 0.0001) and C3 (p = 0.0022) effects
for tissue bacteria (C).
colon cancer in Gpr43−/− mice (Fig. 9E). Antibiotics suppressed
the numbers of tumors in Gpr43−/− mice than that not in WT mice.
Antibiotics also significantly decreased the enlargement of spleen
in Gpr43−/− mice (not shown). Overall, these results indicate that
increased colon cancer formation in Gpr43−/− mice is due in part
to high levels of tissue bacteria.
Discussion
We studied, in depth, the impact of DF, SCFAs, and SCFA receptors
on tissue bacterial load, intestinal inflammation and carcinogene-
sis. Based on early in vitro data with cell lines, it has been proposed
that SCFAs inhibit HDACs to suppress cancer cells [38–40]. How-
ever, this mechanism alone does not fully explain the SCFA effect
on carcinogenesis in vivo. A mounting body of evidence, including
the data presented in this report, suggests that the protective effect
of SCFAs is, in part, mediated by SCFA receptors [27, 31], which
function in a largely HDAC-independent manner. We found that
SCFAs and SCFA receptors promote barrier immunity and sup-
press bacterial invasion, which can induce chronic inflammatory
responses. Importantly, SCFAs, exemplified by C3, and GPR43
have suppressive effects on chronic inflammatory responses and
intestinal carcinogenesis.
We studied both GPR43 and GPR41 but focused our efforts on
GPR43 because the anti-cancer effect of GPR43 was greater than
that of GPR41. The two GPCRs are receptors for C2, C3 and C4
but their affinity to these SCFAs are different [16]. While both
receptors are expressed by intestinal epithelial cells, the distribu-
tion of the two in the body are very different [3, 37]. For example,
GPR43 is expressed by neutrophils, whereas GPR41 is expressed
by adipocytes. Also, the two may be expressed by different cell
types in the intestine. These differences in receptor expression
are likely to account for the observed differences in SCFA recep-
tor functions. Our BM transplantation experiment revealed that
non-BM-derived tissue cells play a major role in mediating the
GPR43-dependent suppression of intestinal inflammation and car-
cinogenesis, while hematopoietic cells play a relatively minor role.
The most likely cells to mediate the GPR43 function are intestinal
epithelial cells, which highly express GPR43 and are effectively
stimulated by SCFAs for barrier immunity [13]. This finding is
in line with a previous report that non-hematopoietic cells are the
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major mediator of the GPR109A effect [31]. However, a minor but
significant role of hematopoietic cells was still observed in both
studies.
SCFAs promote the expression of intestinal tight junction pro-
teins in the steady state and boost anti-microbial responses dur-
ing infection or following gut barrier breach [14, 41]. T cell
responses in the intestine reflect the inflammatory status regu-
lated by SCFAs and their receptors. Particularly, Th17 cells, which
contribute to barrier immunity, undergo expansion during an
acute phase of immune responses but contraction as inflamma-
tory responses subside. Numbers of Th17 cells remain increased in
Gpr43−/− mice along with chronic inflammation. This effect some-
what mirrors that of GPR109A [31]. These results identify impor-
tant roles of SCFAs and their receptors in mounting innate and
adaptive immune responses to suppress bacterial invasion across
the barrier. The increased Th17 cell response in GPR43 deficiency
appears to be a bystander response as the consequence of inflam-
matory responses due to bacterial invasion but we cannot rule
out the possibility that it may involve antigen-specific responses.
This finding clarifies the rather unexpected attenuated inflamma-
tion observed by Sina et al. at an acute phase of DSS-induced
inflammation [29]. It has been recently reported that GPR43 and
GPR109A promote epithelial inflammasome responses [28]. Our
results together with these reports emphasize the defective acute
inflammatory response and associated-gut permeability change in
Gpr43−/− mice following DSS or AOM/DSS treatment, observed
in this study
Sustained high bacterial burden in colon tissues can cause
chronic inflammatory responses. For example, inflammatory
cytokines and chemokines, such as IL-18, IL-22, IL-6 and CXCL1,
which promote effective barrier immunity to ward off invading
bacteria [42–44], were not normally induced at the early phase
in Gpr43−/− mice. During prolonged treatments with DSS or
AOM/DSS, Gpr43−/− mice suffer less than WT mice in the first
few weeks but become more susceptible afterward. This indicates
that SCFA receptors function to coordinately regulate acute and
chronic inflammatory responses. The function of SCFA receptors
in regulating chronic inflammation is closely related to their func-
tion in suppressing intestinal cancer. In APCmin/+ mice, tumors
are formed more in the small, than large, intestine, and thus this
model provides additional insights into SCFA-receptor-regulated
cancer outside the colon. The phenotype of this model indicates
that the SCFA-GPR43 axis has anti-cancer effects in both the small
and large intestines.
Inflammation is frequently linked to carcinogenesis. Our results
indicate that DF and SCFAs, as represented by C3 in this study,
suppress intestinal cancer in GPR43-dependent and independent
manners. Our findings are in line with others’ findings that DF,
SCFAs and SCFA receptors exert suppressive effects on colon can-
cer [27, 31, 45–48] and provide a potential mechanism for the
suppressive function. Our findings underscore the important role
of the SCFA- SCFA receptor axis in suppressing bacterial invasion,
subsequent chronic inflammation and inflammation-associated
intestinal carcinogenesis. Colon cancer development is closely
associated with gut microbiota changes [49–51]. DF changes the
gut microbiota. For example, DF enriches Bacteroidaceae and Bifi-
dobacteriaceae and potentially decrease pathogenic bacteria [52].
Firmicutes, particularly those of the Erysipelotrichaceae family,
are increased in DF deficiency. Moreover, GPR43 functions to
increase beneficial bacterial species [27]. In this study, co-housing
with WT-littermates failed to suppress the elevated chronic Th17
response, bacterial invasion and associated colon cancer develop-
ment in Gpr43−/− mice in response to AOM/DSS-treatment. This
indicates that control of the microbiota by GPR43 does not have
a dominant role on colon cancer development. Rather, the data
underline the importance of host cells in mediating the protective
effect of GPR43. We conclude that the SCFA-GPR43 axis func-
tions to boost barrier immune responses against microbiota and
this response limits persistent bacterial invasion, chronic inflam-
matory responses and colon cancer development.
Materials and methods
Mice, diet, and SCFA administration
All animal experiments were approved by the Purdue Animal
Care and Use Committee (PACUC). CD45.1 C57BL/6 mice and
ApcMin/+ mice were from the Jackson Laboratory (Bar Harbor,
ME). Gpr43−/− mice were purchased from Deltagen (San Mateo,
CA), and Gpr41−/− mice were obtained from Dr. M Yanagisawa
(UT Southwestern Medical Center at Dallas). All mice were on
C57BL/6 background. Gpr43−/− mice were crossed with ApcMin/+
mice to derive ApcMin/+Gpr43−/− mice. The mice were kept at the
Purdue Life Science Animal Facility for at least 12 months prior
to the study. Mice were fed regular rodent chow (Harlan 2018S
Global 18% Protein Rodent Diet) or special DF diets. The special
diets containing different amounts of DF (0% of pectin and inulin
at 1:1 ratio for LFD, 5% for MFD, and 15% for HFD) were custom-
ordered from Envigo. Mice were fed special diets from 3 weeks of
age and/or drinking water containing C3 (80 mM, pH 7.4). Mice
were treated with DSS or AOM/DSS from 5 or 6 weeks of age for
most mice or 11–12 weeks of age for BM chimera mice. When indi-
cated, mice were treated with antibiotics (ampicillin, neomycin,
and metronidazole at 1 g/L and vancomycin at 0.5 g/L). When
indicated (Figs. 4 and 9D, and Supporting Information Fig. 2),
female mice were co-housed for 1–2 weeks before and during the
induction of AOM/DSS-induced colon cancer. Alternatively, WT
and Gpr43−/− mice were housed in cages inoculated with mixed
soiled bedding from WT and Gpr43−/− mice (20% old mixed and
80% new bedding; changed every 3–4 days). The data obtained
with the two methods were similar and therefore were combined.
DSS-induced acute and chronic intestinal
inflammation
For acute intestinal inflammation, mice were on 3.5% DSS in
drinking water for 5 days and then on plain water before they
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were euthanized on day 9. For chronic intestinal inflammation,
mice were treated with 1.5% DSS in drinking water for 7 days
and then with regular water for 7 days. This cycle was repeated
three times. Intestinal tissues were examined by flow cytometry
for T cells and neutrophils and by qRT-PCR for expression of
inflammatory cytokines (IL-6, IL-18, IL-22, and CXCL-1) as
described previously [13, 53]. Primers used for this study were
previously described [13].
Tight junction proteins, tissue bacterial burden, and
cecal bacterial 16S rRNA gene PCR analysis
Mice were assessed for expression of tight junction protein genes
(ocln and tjp1), gut permeability, and tissue bacteria 42 days after
the start of DSS treatment. The expression of ocln and tjp1was
determined by qRT-PCR with the primers: ACC ACT ATG AAA
CAG ACT ACA CG (Ocln-F), GGA GAA CTA CAC GCT ATT AAA
CG (Ocln-R), GAA GAT GAA GAT GAG GAT GGT CA (tjp1-F),
ACC AGT GAT TAG TCC TGT CTT TGT (tjp1-R). Tissue bacterial
levels were determined by q-PCR of a common eubacterial 16S
rRNA gene sequences and normalized by genomic β-actin levels
as previously described [13]. Cecal bacterial 16S rRNA gene PCR
analysis for cohoused animals was performed as described previ-
ously [13, 54].
Gut permeability
For assessing gut permeability, mice were fasted overnight and
orally gavaged with fluorescein isothiocyanate (FITC)–conjugated
dextran (0.2 mg/g of body weight, mean molecular weight of
3000–5000; Sigma- Aldrich, St Louis, MO) using a round-tip feed-
ing needle. Mice were sacrificed 3 h later, and the FITC-dextran
concentration in the plasma was determined with a fluorescent
microplate reader (excitation at 485 nm and emission at 535 nm;
Synergy HT; BioTek, Winooski, VT).
AOM/DSS and APCMin/+-induced models of intestinal
cancer
Mice were treated i.p. with azoxymethane (AOM, 10 mg/kg of
body weight) and rested for 7 days. The mice were then admin-
istered with 1% DSS (36–50 kDa) in drinking water for 7 days
and rested on regular water for 7 days. This cycle was repeated
3 times. Mice were monitored daily for changes in body weight,
signs of illness, and stool score. Mice were sacrificed 62–70 days
post-AOM injection and were assessed for polyp size and number
and organ (spleen and MLN) weight. Colon tissues were paraffin-
embedded and tissue sections were stained with hematoxylin and
eosin. ApcMin/+ mice and ApcMin/+Gpr43−/− mice were similarly
assessed for tumors in the small and large bowels and organ weight
at 4 months of age.
Cell isolation and flow cytometry
For isolation of intestinal LP cells, intestinal tissues were har-
vested into cold PBS and trimmed to remove mesenteries, fat,
and Peyer’s patches. Intestinal tissues were cut into 2 cm pieces.
The epithelial layer was extracted five times with 10 mM EDTA
in HBSS buffer at room temperature for 15 min, and then the
remaining tissues were digested twice at 37°C for 1 h with 1.5
mg/mL collagenase (type 3, Worthington). Collected cells were
stained with antibodies to Gr-1 (RB6-8C5), CD11b (M1/70) and
CD45 (30-F11) for neutrophils or to CD4 (RM4-5) for T cells.
For intracellular staining of IL-17a and IFN-γ, cells were activated
in RPMI 1640 (10% fetal bovine serum) with phorbol myristate
acetate (50 ng/mL), ionomycin (1 mM), and monensin (2mM;
Sigma- Aldrich) for 4 h. Cells were then fixed, permeabilized,
and stained with antibodies to mIL-17A (TC11-18H10.1) or IFNγ
(XMG1.2). For FoxP3 staining, cells were fixed, permeabilized,
and then stained with FoxP3 (FJK-16S) according to the manufac-
turer’s protocol (eBioscience). Detailed gating strategies are found
in Supporting Information Fig. 1.
Bone marrow transplantation
To prepare host mice, WT or Gpr43−/− mice were irradiated at 500
rads, and this was repeated after 4 h. Host mice were injected i.v.
with 1 × 107 BM cells from WT or Gpr43−/− mice. The CD45.1 and
CD45.2 congenic system was used to distinguish donor and recip-
ient cells. Six weeks later, mice were checked for hematopoietic
reconstitution and were treated with AOM and DSS. The marrow
reconstitution efficiency in these animals was >95% (spleen).
Confocal microscopy and histological analysis
Colon tissues, harvested from WT or Gpr43−/− mice subjected to
chronic DSS treatment, were frozen in Tissue-Tek OCT compound
(Sakura) and were cut into 8-μm sections. The sections were fixed
in cold acetone and stained with CY3-labled EU338 (5′-GCT GCC
TCC CGT AGG AGT-3, Eurofins) and Pan-cytokeratin. Confocal
images were collected with a SP5 II laser scanning microscopic sys-
tem (Leica). For histological analysis, sections (6 μm) of paraffin-
embedded intestinal tissues were stained with hematoxylin and
eosin. Histological images were taken at 50× magnification.
Statistical analysis
For weight change and stool score, repeated measures ANOVA was
used to determine group effects (Fig. 1A, 2A, 3A, 6A, and 7B) for
indicated time periods, and after finding a significant group effect,
pairwise comparisons of interest on specific days were made using
two-sample t-tests with Bonferroni’s adjustments to account for
multiple comparisons. For analyzing Fig. 8C, 8E, and 9, two-way
ANOVA was used with an interaction of the two factors, and upon a
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significant interaction, multiple pairwise comparisons were made
using t-tests with Bonferroni adjustments. When no interaction
is evident, results from two-way ANOVA with main effects only
are presented. For comparing multiple groups in Fig. 1B-E, 2B-
E, 6B, 6C and 7C, one-way ANOVA followed by Tukey’s multiple
comparisons test was used. Additionally, Mann-Whitney U-test
(two-sided with statistical significance set at 0.05) was used to
compare two groups of interest (Fig. 3B, 3D, 4 and 5C, 5D, 8A,
and 8B). All error bars indicate SEM. Prism (Graphpad) and SAS
statistical software were used.
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